Recent Updates
Recently added Catalysts

CV7201 mRNA

Phase 1

Rabies | Monoclonal antibody | Other |BioNTech SE|Last Updated: Oct 29, 2018

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
CONTROLLEDDMCBiomarker
Total Trials1
Total Enrollment101
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT02241135RNActive® Rabies Vaccine (CV7201) in Healthy AdultsPHASE1 COMPLETED 101Oct 1, 2013Feb 8, 2018Oct 29, 20181 Germany
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Incidence and severity of serious adverse events (SAEs)/adverse events (AEs) and local tolerability assessment of the vaccination site
up to 64 days after the last vaccination

The occurrence of AEs will be assessed by non-directive questioning of the subject at each visit. Further, AEs volunteered by the subject during or between visits - as subject diary card entries - or detected through observation, physical examination, laboratory test, or other assessments during the entire observation period, will be documented. Subjects will be instructed that they must immediately report any AEs, subjective complaints or objective changes in their well-being to the Investigator or the clinic personnel, regardless of the perceived relationship between the event and the test product. The Investigator is responsible for reporting all AEs in the eCRF that are observed or described by the subject, regardless of their relationship to the trial vaccine or their clinical significance.

Secondary Endpoints
The lowest CV7201 dose to elicit rabies VNTs ≥ 0.5 IE/ml
Rabies VNTs measured 14 days after the 3rd vaccination (Visit 8)
Number of treatment discontinuation due to IMP-related AEs/SAEs
up to 64 days after the last vaccination
Unlock Study Endpoints
Study Design & Arms
AllocationNON_RANDOMIZED
MaskingNONE
ModelPARALLEL
PurposePREVENTION
Treatment Arms
ArmTypeDescription
80 µg CV7201 mRNA shortEXPERIMENTALVaccination by injection on days 0, 7, 28.
160µg CV7201 mRNA shortEXPERIMENTALVaccination by injection on days 0, 7, 28.
80 µg CV7201 mRNA longEXPERIMENTALVaccination by injection on days 0, 28, 56.
160 µg CV7201 mRNA longEXPERIMENTALVaccination by injection on days 0, 28, 56.
320 µg CV7201 mRNA longEXPERIMENTALVaccination by injection on days 0, 28, 56.
640 µg CV7201 mRNA longEXPERIMENTALVaccination by injection on days 0, 28.
200 µg CV7201 mRNA longEXPERIMENTALVaccination by injection on days 0, 28, 56.
400 µg CV7201 mRNA longEXPERIMENTALVaccination by injection on days 0, 28, 56.
Interventions
NameTypeDescription
CV7201 mRNABIOLOGICALCV7201 is composed of 1 RNActive® mRNA that encodes the rabies virus glycoprotein.
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 40 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: 1. Healthy male and female volunteers aged 18 to 40 years inclusive 2. Compliant with protocol procedures and available for clinical follow-up through the last planned visit (V9) 3. Physical examination and laboratory results without clinically significant findings 4. Body Mass ...

Countries:Germany
Unlock Eligibility Criteria